

CONTENTS

Acknowledgements	vii
Contributors	ix
Foreword	xi
Abbreviations	xiii
EXECUTIVE SUMMARY	xv
1. INTRODUCTION	1
1.1 Background and objectives	1
2. EPIDEMIOLOGY AND PUBLIC HEALTH ASPECTS	5
2.1 Organisms of concern	5
2.1.1 <i>Enterobacter sakazakii</i>	5
2.1.2 Other relevant organisms of concern	7
2.2 Scope/Case description	7
2.2.1 Identification of products considered	7
2.2.2 Case definition	8
3. HAZARD IDENTIFICATION	11
3.1 Category "A" organisms – Clear evidence of causality	11
3.2 Category "B" organisms – Causality plausible, but not yet demonstrated	11
3.3 Category "C" organisms – Causality less plausible or not yet demonstrated	12
4. HAZARD CHARACTERIZATION	13
4.1 Populations at risk	13
4.2 Dose-response	13
5. EXPOSURE ASSESSMENT	15
5.1 Exposure to infant formula/breastfeeding rates	15
5.2 Developing countries	16
5.3 Microbial aspects of manufacture and use of powdered infant formula	16

5.3.1	Manufacture	17
5.3.2	Control of ingredient quality	17
5.3.3	Processing	18
5.3.4	Post-processing and packaging	20
5.3.5	Hazard Analysis Critical Control Point (HACCP) in the manufacture of powdered infant formula	21
5.3.6	Monitoring	22
5.3.7	Microbiological specifications	24
5.3.8	Reconstitution and use	25
5.3.9	Labelling and preparation	26
5.3.10	Storage and handling of prepared formula	28
5.3.11	Education	28
6.	RISK CHARACTERIZATION	31
6.1	Approaches and outputs	31
6.2	Evaluation of potential risk reduction options for formula-fed infants	32
7.	RISK REDUCTION STRATEGIES FOR FORMULA-FED INFANTS	35
7.1	Reducing the concentration/prevalence of intrinsic contamination of powdered infant formula by <i>E. sakazakii</i>	35
7.2	Reducing the level of contamination through heating reconstituted powdered infant formula prior to use	35
7.3	Minimizing the chance of contamination of reconstituted formula during preparation	36
7.4	Minimizing the growth of <i>E. sakazaki</i> following reconstitution prior to consumption	36
8.	KEY FINDINGS AND RECOMMENDATIONS	37
8.1	Key findings	37
8.2	Recommendations	38
8.2.1	To member countries, NGOs, FAO and WHO	38
8.2.2	To Codex (e.g. CCFH)	39
8.2.3	To member countries, FAO, WHO, Codex and NGOs	39
8.2.4	To FAO, WHO and the scientific community	39

REFERENCES	41
APPENDIX A LIST OF BACKGROUND PAPERS	47
APPENDIX B DATA RECEIVED IN RESPONSE TO THE FAO/WHO CALL FOR DATA	49
APPENDIX C RISK ASSESSMENT	51